PharmaCyte Biotech Inc (PMCB) Expected Move

Tracking the PMCB expected move helps you see how far PharmaCyte Biotech Inc's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. PharmaCyte Biotech Inc's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the PMCB expected move for this week's options, in real time.

The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For PMCB, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The PMCB expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks PharmaCyte Biotech Inc is unlikely to go.

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant.

It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the PMCB expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The PharmaCyte Biotech Inc expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about PMCB.